Navigation Links
First evidence that obesity gene is risk factor for melanoma
Date:3/4/2013

The research shows that people with particular variations in a stretch of DNA within the FTO gene, called intron 8, could be at greater risk of developing melanoma.

Variations in a different part of the FTO gene, called intron 1, are already known to be the most important genetic risk factor for obesity and overeating. These variants are linked to Body Mass Index (BMI) a measure of a person's shape based on their weight and height. Having a high BMI can increase the risk of various diseases including type 2 diabetes, kidney disease, womb (endometrial) cancer and more.

But this research is the first to reveal that the gene affects a disease melanoma which isn't linked to obesity and BMI.

The results, published in Nature Genetics, suggest that FTO has a more wide-ranging role than previously suspected, with different sections of the gene being involved in various diseases.

Study author, Dr Mark Iles, Cancer Research UK scientist at the University of Leeds, said: "This is the first time to our knowledge that this major obesity gene, already linked to multiple illnesses, has been linked to melanoma. This raises the question whether future research will reveal that the gene has a role in even more diseases?

"When scientists have tried to understand how the FTO gene behaves, so far they've only examined its role in metabolism and appetite. But it's now clear we don't know enough about what this intriguing gene does.

"This reveals a hot new lead for research into both obesity-related illnesses and skin cancer."

The researchers examined tumour samples in more than 13,000 melanoma patients and almost 60,000 unaffected people from around the world.

Malignant melanoma is the fifth most common cancer in the UK with around 12,800 new cases and around 2,200 deaths each year.

Dr Julie Sharp, Cancer Research UK's senior science information manager, said: "These are fascinating early findings that, if confirmed in further research, could potentially provide new targets for the development of drugs to treat melanoma.

"Advances in understanding more about the molecules driving skin cancer have already enabled us to develop important new skin cancer drugs that will make a real difference for patients.

"But it doesn't detract from the importance of reducing your risk of the disease by enjoying the sun safely on winter breaks abroad and avoiding sunbeds. Getting a painful sunburn just once every two years can triple the risk of melanoma."


'/>"/>

Contact: Rachel Barson
r.barson@leeds.ac.uk
01-133-432-060
University of Leeds
Source:Eurekalert

Related medicine news :

1. Researchers describe first functional HIV cure in an infant
2. Zoloft Lawsuit News: Bernstein Liebhard LLP Notes New Pretrial Order in Federal Zoloft Litigation Establishing Tentative Date for First Bellwether Trial
3. Geoff Neupert, StrongFirst Master Kettlebell Instructor, Releases New Video Detailing How To Make Seemingly Unlimited Progress With Only One Kettlebell
4. Federal NuvaRing Blood-Clotting Lawsuits Report: Resource4thePeople Updates Consumers with News That First Bellwether Trial Rescheduled to July
5. U.N. Secretary-General Appoints Ray Chambers as His First Special Envoy for the Financing of the Health-Related Millennium Development Goals
6. Geoff Neupert, StrongFirst Master Kettlebell Instructor, Releases New Video Showing the Best Upper Body Exercises to Use in Traditional Kettlebell Workouts
7. NYC Chiropractor Will Soon be the First Chiropractor in New York to Offer ISCS 2.0 Non Surgical Spinal Decompression
8. Educational First Steps Hosts Early Childhood Education Conference and Symposium for Over 500 Early Childhood Professionals
9. The Triangle’s First Orthopaedic Ambulatory Surgery Center Officially Opens in Brier Creek
10. $3.35 Million Awarded in First Transvaginal Mesh Trial Verdict: Prompts McDonaldWorley.com Support Expansion
11. OHSU scientists first to grow liver stem cells in culture, demonstrate therapeutic benefit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... The adage “Show, don’t tell” applies perfectly ... in the company’s esteemed VISION House demonstration project series. Manifesting the concept of right-sized ... resources they need to live affordably and abundantly without unduly taxing the resources of ...
(Date:4/21/2017)... ... 21, 2017 , ... The VIA Agency , a ... Theravent, Inc. , the makers of a revolutionary new device clinically proven ... now working to expand distribution in anticipation of a national launch. VIA will ...
(Date:4/21/2017)... Arvada, CO (PRWEB) , ... April 21, 2017 ... ... health and performance system, has partnered with O2X , an active lifestyle ... are focused on improving the health of firefighters, police offers, first responders, military ...
(Date:4/21/2017)... ... April 21, 2017 , ... Alive for Wellness ... to overcome their mental health struggles. The Alive team uses advanced behavioral sciences ... approach in dealing with a mental health struggle is based on 10 modalities ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... anticipated Regional Primary Care Spring Symposium on April 1, 2017 in Santa Rosa. ... offering physicians and healthcare providers an opportunity to learn about cutting edge treatments, ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  Cogentix Medical, Inc. (NASDAQ: CGNT), a global ... Uro/Gyn and Gynecology markets with innovative and proprietary ... the Company as Senior Vice President, Marketing & ... Keswani will report directly to Darin Hammers ... is delighted that Ash has joined the Cogentix ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology: